TB Drug Discovery
The GMB unit is leading a major effort to discover new drugs for the treatment of tuberculosis (TB) as part of an INTEGRATED PROJECT funded by the European Commission for five years from January 2006. The New Medicines for Tuberculosis Project, NM4TB, follows the highly successful X-TB
(http://www.pasteur.fr/recherche/X-TB/) programme that generated over 60 publications and 30 crystal structures of important proteins and drug targets from Mycobacterium tuberculosis .
NM4TB aims to discover and develop new drugs for the treatment of TB through an integrated approach implemented by a team, that combines some of Europe's leading academic TB researchers, with a major pharmaceutical company and three SMEs, all with a strong commitment to discovering new anti-infective agents. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its pipeline. For more details consult the NM4TB website (http://www.pasteur.fr/recherche/NM4TB/).
Website Copyright © 2000-2006 by the Institut Pasteur.
All rights reserved
DISCLAIMER
The information contained in this webpage is provided in good faith, but no
warranty, nor any legal liability or responsibility for any purpose for
which the data are used, is given.
